Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer
J Amann, S Kalyankrishna, PP Massion, JE Ohm… - Cancer research, 2005 - AACR
Epidermal growth factor receptor (EGFR) is occasionally amplified and/or mutated in non–
small cell lung cancer (NSCLC) and can be coexpressed with other members of the HER …
small cell lung cancer (NSCLC) and can be coexpressed with other members of the HER …
EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head
J Clark, J Cools, DG Gilliland - PLoS Medicine, 2005 - journals.plos.org
EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly
Head | PLOS Medicine Skip to main content Advertisement PLOS Medicine Browse Current …
Head | PLOS Medicine Skip to main content Advertisement PLOS Medicine Browse Current …
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
L Regales, MN Balak, Y Gong, K Politi, A Sawai, C Le… - PloS one, 2007 - journals.plos.org
Background The EGFR T790M mutation confers acquired resistance to kinase inhibitors in
human EGFR mutant lung adenocarcinoma, is occasionally detected before treatment, and …
human EGFR mutant lung adenocarcinoma, is occasionally detected before treatment, and …
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With …
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal …
L Paz-Ares, JM Sanchez, A Garcia-Velasco… - Journal of Clinical …, 2006 - ascopubs.org
7020 Background: The EGFR TK inhibitor erlotinib is a standard treatment in previously
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …
[引用][C] Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the …
Fig 1. Effects of L747S and T790M in the sensitivity of L858R-EGFR to gefitinib and
erlotinib.(A) Ba/F3 cells stably containing constructs with the L858R, L858R-L747S or …
erlotinib.(A) Ba/F3 cells stably containing constructs with the L858R, L858R-L747S or …
[HTML][HTML] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
L Huang, L Fu - Acta Pharmaceutica Sinica B, 2015 - Elsevier
Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …
[HTML][HTML] EGFR targeted therapy in lung cancer; an evolving story
C Bartholomew, L Eastlake, P Dunn… - Respiratory medicine case …, 2017 - Elsevier
Specific oncogenes with driver mutations, such as the Epidermal Growth Factor Receptor
(EGFR 1) gene can lead to non-small-cell lung cancer formation. Identification of these …
(EGFR 1) gene can lead to non-small-cell lung cancer formation. Identification of these …
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
M Sudo, TM Chin, S Mori, NB Doan, JW Said… - Cancer chemotherapy …, 2013 - Springer
Purpose Sensitivity to a tyrosine kinase inhibitor (TKI) is correlated with the presence of
somatic mutations that affect the kinase domain of epidermal growth factor receptor (EGFR) …
somatic mutations that affect the kinase domain of epidermal growth factor receptor (EGFR) …
EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer
Despite the success of treating EGFR-mutant lung cancer patients with EGFR tyrosine
kinase inhibitors (TKI), all patients eventually acquire resistance to these therapies. Although …
kinase inhibitors (TKI), all patients eventually acquire resistance to these therapies. Although …